560 related articles for article (PubMed ID: 27071307)
1. Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.
Gao Y; Gao J; Li M; Zheng Y; Wang Y; Zhang H; Wang W; Chu Y; Wang X; Xu M; Cheng T; Ju Z; Yuan W
J Hematol Oncol; 2016 Apr; 9():36. PubMed ID: 27071307
[TBL] [Abstract][Full Text] [Related]
2. Rheb1-mTORC1 maintains macrophage differentiation and phagocytosis in mice.
Wang X; Li M; Gao Y; Gao J; Yang W; Liang H; Ji Q; Li Y; Liu H; Huang J; Cheng T; Yuan W
Exp Cell Res; 2016 Jun; 344(2):219-28. PubMed ID: 27163399
[TBL] [Abstract][Full Text] [Related]
3. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
[TBL] [Abstract][Full Text] [Related]
4. [Roles of mTORC1 in acute myeloid leukemia].
Hoshii T; Hirao A
Rinsho Ketsueki; 2015 Apr; 56(4):359-65. PubMed ID: 25971265
[TBL] [Abstract][Full Text] [Related]
5. Genetic and pharmacological inhibition of Rheb1-mTORC1 signaling exerts cardioprotection against adverse cardiac remodeling in mice.
Wu X; Cao Y; Nie J; Liu H; Lu S; Hu X; Zhu J; Zhao X; Chen J; Chen X; Yang Z; Li X
Am J Pathol; 2013 Jun; 182(6):2005-14. PubMed ID: 23567640
[TBL] [Abstract][Full Text] [Related]
6. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.
Zeng Z; Shi YX; Tsao T; Qiu Y; Kornblau SM; Baggerly KA; Liu W; Jessen K; Liu Y; Kantarjian H; Rommel C; Fruman DA; Andreeff M; Konopleva M
Blood; 2012 Sep; 120(13):2679-89. PubMed ID: 22826565
[TBL] [Abstract][Full Text] [Related]
7. Oligodendrocyte precursor cell-intrinsic effect of Rheb1 controls differentiation and mediates mTORC1-dependent myelination in brain.
Zou Y; Jiang W; Wang J; Li Z; Zhang J; Bu J; Zou J; Zhou L; Yu S; Cui Y; Yang W; Luo L; Lu QR; Liu Y; Chen M; Worley PF; Xiao B
J Neurosci; 2014 Nov; 34(47):15764-78. PubMed ID: 25411504
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of Glutamate Transporter EAAT4 by Conditional Knockout of Rheb1 in Cerebellar Purkinje Cells.
Jiang NW; Wang DJ; Xie YJ; Zhou L; Su LD; Li H; Wang QW; Shen Y
Cerebellum; 2016 Jun; 15(3):314-21. PubMed ID: 26194056
[TBL] [Abstract][Full Text] [Related]
9. SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.
Meng H; Jin Y; Liu H; You L; Yang C; Yang X; Qian W
J Hematol Oncol; 2013 Feb; 6():18. PubMed ID: 23415012
[TBL] [Abstract][Full Text] [Related]
10. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
[TBL] [Abstract][Full Text] [Related]
11. Rheb1 is required for mTORC1 and myelination in postnatal brain development.
Zou J; Zhou L; Du XX; Ji Y; Xu J; Tian J; Jiang W; Zou Y; Yu S; Gan L; Luo M; Yang Q; Cui Y; Yang W; Xia X; Chen M; Zhao X; Shen Y; Chen PY; Worley PF; Xiao B
Dev Cell; 2011 Jan; 20(1):97-108. PubMed ID: 21238928
[TBL] [Abstract][Full Text] [Related]
12. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
[TBL] [Abstract][Full Text] [Related]
13. Genetic deletion of Rheb1 in the brain reduces food intake and causes hypoglycemia with altered peripheral metabolism.
Yang W; Jiang W; Luo L; Bu J; Pang D; Wei J; Du C; Xia X; Cui Y; Liu S; Mao Q; Chen M
Int J Mol Sci; 2014 Jan; 15(1):1499-510. PubMed ID: 24451134
[TBL] [Abstract][Full Text] [Related]
14. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
15. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.
Makovski V; Jacob-Hirsch J; Gefen-Dor C; Shai B; Ehrlich M; Rechavi G; Kloog Y
Cell Death Dis; 2014 Dec; 5(12):e1557. PubMed ID: 25476905
[TBL] [Abstract][Full Text] [Related]
16. Repression of Mammalian Target of Rapamycin Complex 1 Inhibits Intestinal Regeneration in Acute Inflammatory Bowel Disease Models.
Guan Y; Zhang L; Li X; Zhang X; Liu S; Gao N; Li L; Gao G; Wei G; Chen Z; Zheng Y; Ma X; Siwko S; Chen JL; Liu M; Li D
J Immunol; 2015 Jul; 195(1):339-46. PubMed ID: 26026060
[TBL] [Abstract][Full Text] [Related]
17. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
18. Cardiac ablation of Rheb1 induces impaired heart growth, endoplasmic reticulum-associated apoptosis and heart failure in infant mice.
Cao Y; Tao L; Shen S; Xiao J; Wu H; Li B; Wu X; Luo W; Xiao Q; Hu X; Liu H; Nie J; Lu S; Yuan B; Han Z; Xiao B; Yang Z; Li X
Int J Mol Sci; 2013 Dec; 14(12):24380-98. PubMed ID: 24351823
[TBL] [Abstract][Full Text] [Related]
19. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.
Fialin C; Larrue C; Vergez F; Sarry JE; Bertoli S; Mansat-De Mas V; Demur C; Delabesse E; Payrastre B; Manenti S; Roche S; Récher C
Leukemia; 2013 Feb; 27(2):325-35. PubMed ID: 22902361
[TBL] [Abstract][Full Text] [Related]
20. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
